Literature DB >> 6804494

Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La.

C A Wasicek, M Reichlin.   

Abstract

Among 55 systemic lupus erythematosus patients having antibodies to Ro and/or La, two major groups were distinguished by titration of sera in counterimmunoelectrophoresis. The first group (30 patients) had antibodies to Ro alone. This was associated with a high incidence of antibodies to DNA (77%) and serious renal disease (53%). The second group (23 patients) had antibodies to Ro and La, and this was associated with a lower incidence of antibodies to DNA (30%) and a very low incidence of nephritis (9%). In this group a phenomenon of linkage of anti- Ro and anti-La titers was observed. Additionally two patients with only anti-La were found. Neither had clinically apparent renal disease. Thus, systemic lupus erythematosus patients with anti-Ro fall into two subgroups that differ considerably in their prevalence of anti-DNA and serious renal disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6804494      PMCID: PMC370138          DOI: 10.1172/jci110523

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Resolution of the identity of certain antigen-antibody systems in systemic lupus erythematosus and Sjögren's syndrome: an interlaboratory collaboration.

Authors:  M Alspaugh; P Maddison
Journal:  Arthritis Rheum       Date:  1979-07

Review 2.  Immune complex disease in experimental animals and man.

Authors:  C G Cochrane; D Koffler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

3.  Precipitating antibody to D.N.A. detected by two-stage electroimmunodiffusion. Study in S.L.E. and in rheumatoid arthritis.

Authors:  G D Johnson; J P Edmonds; E J Holborow
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

4.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.

Authors:  E M Tan; P H Schur; R I Carr; H G Kunkel
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

5.  Correlation of a precipitin reaction to an RNAprotein antigen and a low prevalence of nephritis in patients with systemic lupus erythematosus.

Authors:  M Reichlin; M Mattioli
Journal:  N Engl J Med       Date:  1972-04-27       Impact factor: 91.245

6.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

Authors:  G C Sharp; W S Irvin; E M Tan; R G Gould; H R Holman
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

7.  Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors:  L A Aarden; E R de Groot; T E Feltkamp
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

8.  The clinical significance of autoantibodies to a soluble cytoplasmic antigen in systemic lupus erythematosus and other connective tissue diseases.

Authors:  P Maddison; H Mogavero; T T Provost; M Reichlin
Journal:  J Rheumatol       Date:  1979 Mar-Apr       Impact factor: 4.666

9.  A soluble acidic protein of the cell nucleus which reacts with serum from patients with systemic lupus erythermatosus and Sjögren's syndrome.

Authors:  M Akizuki; R Powers; H R Holman
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

10.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

View more
  42 in total

1.  HLA class II restriction of autoantibody production in patients with systemic lupus erythematosus.

Authors:  H A Stephens; N J McHugh; P J Maddison; D A Isenberg; K I Welsh; G S Panayi
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 2.  Significance of the Ro antigen system.

Authors:  M Reichlin
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

Review 3.  Autoantibodies to the RoRNP particles.

Authors:  M Reichlin
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

4.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

5.  Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations.

Authors:  M Tikly; S Burgin; P Mohanlal; A Bellingan; J George
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

6.  Heterogeneity of the Ro/SSA antigen. Different molecular forms in lymphocytes and red blood cells.

Authors:  M D Rader; C O'Brien; Y S Liu; J B Harley; M Reichlin
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

7.  Clinical and serological features of patients with autoantibodies to GW/P bodies.

Authors:  Rahima A Bhanji; Theophany Eystathioy; Edward K L Chan; Donald B Bloch; Marvin J Fritzler
Journal:  Clin Immunol       Date:  2007-09-17       Impact factor: 3.969

8.  Identification and purification of a 55K polypeptide in Sjögren's syndrome A antigen.

Authors:  P R Smith; P J Venables; D Williams; R N Maini
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

9.  Sera from patients with rheumatic diseases recognize different epitope regions on the 52-kD Ro/SS-A protein.

Authors:  B Bozic; G J Pruijn; B Rozman; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

10.  The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms.

Authors:  M B Frank; K Itoh; A Fujisaku; P Pontarotti; M G Mattei; B R Neas
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.